GlassScriptPhysician profile
Monique Lariviere
NPI 1407447378
$5,519.36
in general payments reported to CMS, 2019-2025
27 companies · $73.74 in 2025
The $73.74 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,251 · 2022: $2,853 · 2023: $1,290 · 2024: $52.07 · 2025: $73.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $806.17 | 2021-2023 | Breztri, Fasenra, Symbicort |
| Glaxosmithkline, LLC. | $719.13 | 2021-2023 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.50 | 2021-2023 | Ofev |
| Grifols USA, LLC | $472.08 | 2021-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $442.88 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $330.70 | 2022-2023 | Yupelri |
| Amgen INC. | $257.88 | 2021-2025 | Tezspire |
| Philips North America LLC | $236.13 | 2021-2022 | |
| Genentech USA, INC. | $190.27 | 2021-2023 | Xolair |
| Jazz Pharmaceuticals INC. | $188.09 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.00 | 2021-2023 | Glassia |
| Genzyme Corporation | $169.98 | 2022-2023 | |
| Harmony Biosciences LLC | $162.63 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $111.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $107.21 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $99.96 | 2022-2023 | Smartvest |
| Axsome Therapeutics, INC. | $84.59 | 2023 | Sunosi |
| Baxter Healthcare | $80.20 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $63.01 | 2021-2023 | Tyvaso |
| Biomerieux INC | $48.78 | 2021 | |
| Inogen, INC. | $37.53 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Teva Pharmaceuticals USA, INC. | $35.50 | 2021 | |
| Lilly USA, LLC | $30.39 | 2024 | Mounjaro |
| Gilead Sciences, INC. | $23.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.68 | 2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $21.60 | 2021 | |
| Merck Sharp & Dohme LLC | $17.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Lariviere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.